Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Cephalosporin Drugs Market from 2024 to 2025?
The market size for cephalosporin drugs has witnessed consistent growth over the past few years. It is projected to increase from $16.56 billion in 2024 to $17.34 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.7%. The expansion during this historic period can be credited to a rise in bacterial infections, growing antibiotic resistance, an increase in healthcare spending, and a heightened demand for generic drugs.
What Is the Projected Market Size of the Cephalosporin Drugs Market?
The market size of cephalosporin drugs is anticipated to steadily increase in the coming years, reaching a valuation of $20.64 billion in 2029 with a compound annual growth rate (CAGR) of 4.4%. This projected growth during the forecasting period can be associated with factors such as a rising geriatric population, growing understanding of bacterial infections, an increasing number of hospitalisations and the ongoing development of new cephalosporin compounds. Trends to watch for in this forecast period are advancements in drug formulation techniques, the modernisation of manufacturing methods, the creation of new cephalosporin derivatives, and breakthroughs in drug delivery technology.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24187&type=smp
Who are the Major Competitors in the Cephalosporin Drugs Market Outlook?
Major companies operating in the cephalosporin drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, Abbott Laboratories, Novartis AG, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Baxter International, Macleods Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Ltd., Mankind Pharma Limited, Aristo Pharmaceuticals Ltd, Hetero Drugs Ltd, Covalent Laboratories Private Limited.
What Is Fueling Growth in the Cephalosporin Drugs Market?
The cephalosporin drugs market is likely to expand as a result of the increasing incidence of infectious diseases. These are diseases instigated by microorganisms such as parasites, fungi, viruses, or bacteria that can be transmitted from person to person. The rise in such illnesses stems from growing antimicrobial resistance, which complicates the curing process for previously manageable infections, leading to more prevalent and durable ailments. Cephalosporin drugs, known for their broad-spectrum antibacterial properties, are effective in treating various bacterial infections, helping to curtail the treatment period by providing quick and dependable relief, thus enhancing patient outcomes. For example, the Department of Health and Human Services, a US-based government agency, stated in November 2023 that cases of newly reported chronic hepatitis B (a viral infection impacting the liver, potentially leading to both acute and chronic disease) surged by 11% in 2022 in comparison to 2021. Hence, the rise in infectious diseases is stimulating the growth of the cephalosporin drugs market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24187&type=smp
Which Cephalosporin Drugs Market Segments Are Growing the Fastest?
The cephalosporin drugs market covered in this report is segmented –
1) By Generation: First Generation, Second Generation, Third Generation, Fourth Generation, Fifth Generation
2) By Route of Administration: Oral, Parenteral, Topical
3) By Application: Skin Infection, Respiratory Tract Infection, Urinary Tract Infection
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By First Generation: Cefazolin, Cephradine, Cephalexin
2) By Second Generation: Cefuroxime, Loracarbef, Cefaclor, Cefprozil
3) By Third Generation: Ceftriaxone, Cefdinir, Cefotaxime, Ceftazidime
4) By Fourth Generation: Cefepime, Cefpirome
5) By Fifth Generation: Ceftaroline, Ceftobiprole
Which Industry Trends Are Shaping the Future of the Cephalosporin Drugs Market?
Leading firms in the cephalosporin drugs market are concentrating their efforts on creating innovative solutions like treatments for gram-negative bacterial infections. This is in response to the growing global issue of antimicrobial resistance and drug-resistant infections. Treatments for gram-negative bacterial infections involve the use of targeted antibiotics to eradicate these bacteria, known for their unique cellular structure that increases their resistance to most antibiotics. For example, in May 2024, Shionogi & Co. Ltd., a pharmaceutical company based in Japan, launched FETROJA (Cefiderocol). This new antibiotic is engineered to fight serious gram-negative bacterial infections, even those that are immune to other drugs. With its unique Trojan horse approach, it can bypass multiple resistance barriers, providing a vital alternative for patients with restricted treatment options.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cephalosporin-drugs-global-market-report
Which Countries Are Leading the Cephalosporin Drugs Market?
North America was the largest region in the cephalosporin drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cephalosporin drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/customise?id=24187&type=smp
This Report Delivers Insight On:
1. How big is the cephalosporin drugs market, and how is it changing globally?
2. Who are the major companies in the cephalosporin drugs market, and how are they performing?
3. What are the key opportunities and risks in the cephalosporin drugs market right now?
4. Which products or customer segments are growing the most in the cephalosporin drugs market?
5. What factors are helping or slowing down the growth of the cephalosporin drugs market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model